XT
RETA

XTX Topco’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

XTX Topco’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-9,679
Closed -$317K – 1168
2022
Q1 		$317K Buy
+9,679
New +$287K 0.14% 249

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

XTX Topco's RETA Position: Q2 2022 in Review

XTX Topco sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2022, closing a stake of 9,679 shares — an estimated $317K sold.

XTX Topco first reported a position in RETA in Q1 2022 and held it in 1 quarter. The position peaked at $317K in Q1 2022. 146 funds tracked by Wall St. Rank hold RETA as of Q2 2022.

  • XTX Topco reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2022 after selling out during the quarter.
  • XTX Topco sold 9,679 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2022, an estimated $317K.
  • XTX Topco first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2022 and held it in 1 quarter.
  • XTX Topco's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $317K in Q1 2022.
  • 146 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2022.

Based on XTX Topco's 13F filing for Q2 2022, filed 15 Aug 2022.